Merit Cudkowicz
Massachusetts General Hospital · Professor of Neurology of the Harvard Medical School · NeuroClinical Trials Unit (Massachusetts General Hospital)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Merit Cudkowicz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:12 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT07410806 · HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD · active not recruiting · Amyotrophic Lateral Sclerosis (ALS) · principal investigator
- Ph2/Ph3NCT05842941 · HEALEY ALS Platform Trial - Regimen G DNL343Merit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT05740813 · HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262Merit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT05136885 · HEALEY ALS Platform Trial - Regimen E SLS-005 - TrehaloseMerit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT04615923 · HEALEY ALS Platform Trial - Regimen D PridopidineMerit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT04436497 · HEALEY ALS Platform Trial - Regimen A ZilucoplanMerit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT04436510 · HEALEY ALS Platform Trial - Regimen B VerdiperstatMerit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT04414345 · HEALEY ALS Platform Trial - Regimen C CNM-Au8Merit E. Cudkowicz, MD · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT04297683 · HEALEY ALS Platform Trial - Master ProtocolMerit E. Cudkowicz, MD · active not recruiting · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2NCT02017912 · Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSBrainstorm-Cell Therapeutics · completed · Amyotrophic Lateral Sclerosis (ALS) · principal investigator
- Ph2NCT01854294 · GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)Genervon Biopharmaceuticals, LLC · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph3NCT01281189 · Phase 3 Study of Dexpramipexole in ALSKnopp Biosciences · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph1NCT01041222 · Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene MutationsIonis Pharmaceuticals, Inc. · completed · Familial Amyotrophic Lateral Sclerosis · study chair
- Ph2NCT00931944 · Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)Knopp Biosciences · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT00818389 · Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)Massachusetts General Hospital · terminated · Amyotrophic Lateral Sclerosis · principal investigator
- Ph2/Ph3NCT00706147 · Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral SclerosisUniversity of Miami · completed · Amyotrophic Lateral Sclerosis · principal investigator
- Ph3NCT00608881 · Coenzyme Q10 in Huntington's Disease (HD)Massachusetts General Hospital · terminated · Huntington's Disease · principal investigator
- Ph2NCT00561366 · A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALSCytRx · withdrawn · Amyotrophic Lateral Sclerosis · principal investigator
- Ph3NCT00349622 · Clinical Trial Ceftriaxone in Subjects With ALSMassachusetts General Hospital · completed · Amyotrophic Lateral Sclerosis, ALS · principal investigator
- Ph2NCT00244244 · A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALSCytRx · completed · Amyotrophic Lateral Sclerosis (ALS) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)U01NS077179 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2011 to 2026 · $2,770,869 awarded in 2026Same name and institution; not confirmed by an ID
- Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXTOT2NS138339 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2024 to 2026 · $2,981,723 awarded in 2026Same name and institution; not confirmed by an ID
- Coenzyme Q10 in Huntingtons DiseaseU01NS052592 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2008 to 2013 · $1,349,440 awarded in 2013Grant number is on one of their registry trials
- Clinical Trial of Ceftriaxone in Subjects with ALSU01NS049640 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2006 to 2012 · $3,575,101 awarded in 2012Grant number is on one of their registry trials
- CLINICAL TRIAL: OPEN-LABEL ARIMOCLOMOL EXTENSION PROTOCOLM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 1998 to 2008 · $162 awarded in 2008Same name and institution; not confirmed by an ID
- Coenzyme Q10 in Huntington's DiseaseR01NS052592 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2005 to 2007 · $1,487,896 awarded in 2007Same name and institution; not confirmed by an ID
- DOUBLE BLIND STUDY OF MINOCYCLINE IN HDR01FD002588 · FDA · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2005 to 2007 · $411,803 awarded in 2007Same name and institution; not confirmed by an ID
- Metabolomic Signatures in ALSR21ES013470 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2004 to 2005 · $142,420 awarded in 2005Same name and institution; not confirmed by an ID
- Clinical Trial of Ceftriaxone in ALSR01NS049640 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2004 · $1,580,123 awarded in 2004Same name and institution; not confirmed by an ID
- CLINICAL TRIAL OF TOPIRAMATE IN ALSR01NS039988 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2000 to 2003 · $61,000 awarded in 2003Same name and institution; not confirmed by an ID
- RISK FACTORS AND THERAPEUTIC STRATEGIES IN ALSK08NS001896 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 1996 to 2000 · $113,751 awarded in 2000Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Coordination and Statistics for Coenzyme Q10 in Huntington's DiseaseR01NS052619 · NINDS · UNIVERSITY OF ROCHESTER · PI Michael P McDermott · fiscal years 2005 to 2014Named on NCT00608881
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:12 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med · 2022807 citationsRCR 65.6
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.Lancet Neurol · 2013503 citationsRCR 14.7
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med · 2020475 citationsRCR 23.5
- 425 citationsRCR 20.2
- Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.Muscle Nerve · 2011247 citationsRCR 7.8
- Trial of celecoxib in amyotrophic lateral sclerosis.Ann Neurol · 2006244 citationsRCR 5.7
- A clinical trial of creatine in ALS.Neurology · 2004230 citationsRCR 5.3
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.N Engl J Med · 2018230 citationsRCR 9.7
- 221 citationsRCR 7.7
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.JAMA Neurol · 2014210 citationsRCR 7.3